No Blanket Immunity For COVID-19 Vaccine Liabilities, Says EU
Industry Working With Governments On Compensation Systems
As the race to develop COVID-19 vaccines continues, EU member states are ready to financially cover certain of the companies’ risks, but not to change the rules on liability. Transparency proponents are calling for all contracts on vaccine purchases to be made public.
You may also be interested in...
A senior European Commission official has said that the first COVID-19 vaccinations are expected before the end of 2020, and confirmed that pharmaceutical companies developing vaccines will be liable for their products under existing laws.
Companies developing medical countermeasures for COVID-19 need to become familiar with divergences in the liability protection offered by different countries with regard to possible safety issues that may arise when products are fast-tracked for public health reasons. By doing so they can adopt a systematic process for prospectively evaluating and managing international risks, say Dan Kracov, Lincoln Tsang and Alexander Roussanov.
A new EU-wide strategy on procuring potential COVID-19 vaccines through advance purchase agreements has been launched, replacing earlier fragmented efforts by some member states.